1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Global Beyond the Pill Market
4.
Voice of Customer
4.1.
Brand Awareness
4.2.
Factors Contributing to switch over to Beyond the Pill
4.3.
Barriers to Adoption of Beyond the Pill
5.
Executive Summary
6. Global Beyond the
Pill Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Therapeutic Area (Diabetes, Oncology, Cardiovascular
Diseases, Asthma, Others)
6.2.2.
By Offerings (Services, Monitoring, Assistance,
Information, Education)
6.2.3.
By Company (2020)
6.2.4. By
Region
6.3.
Product Market Map
7. North America Beyond
the Pill Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Therapeutic Area
7.2.2.
By Offerings
7.2.3.
By Country
7.3.
North America: Country Analysis
7.3.1.
United States Beyond the Pill Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Therapeutic Area
7.3.1.2.2.
By Offerings
7.3.2.
Mexico Beyond the Pill Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Therapeutic Area
7.3.2.2.2.
By Offerings
7.3.3.
Canada Beyond the Pill Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Therapeutic Area
7.3.3.2.2.
By Offerings
8. Europe Beyond the
Pill Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Therapeutic Area
8.2.2.
By Offerings
8.2.3.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Beyond the Pill Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Therapeutic Area
8.3.1.2.2.
By Offerings
8.3.2.
Germany Beyond the Pill Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Therapeutic Area
8.3.2.2.2.
By Offerings
8.3.3.
United Kingdom Beyond the Pill Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Therapeutic Area
8.3.3.2.2.
By Offerings
8.3.4.
Italy Beyond the Pill Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Therapeutic Area
8.3.4.2.2.
By Offerings
8.3.5.
Spain Beyond the Pill Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Therapeutic Area
8.3.5.2.2.
By Offerings
9. Asia-Pacific Beyond
the Pill Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By Therapeutic Area
9.2.2.
By Offerings
9.2.3.
By Country
9.3.
Asia-Pacific: Country Analysis
9.3.1.
China Beyond the Pill Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Therapeutic Area
9.3.1.2.2.
By Offerings
9.3.2.
India Beyond the Pill Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Therapeutic Area
9.3.2.2.2.
By Offerings
9.3.3.
South Korea Beyond the Pill Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Therapeutic Area
9.3.3.2.2.
By Offerings
9.3.4.
Japan Beyond the Pill Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Therapeutic Area
9.3.4.2.2.
By Offerings
9.3.5.
Australia Beyond the Pill Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Therapeutic Area
9.3.5.2.2.
By Offerings
10. South America Beyond
the Pill Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1.
By Therapeutic Area
10.2.2.
By Offerings
10.2.3.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Beyond the Pill Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Therapeutic Area
10.3.1.2.2.
By Offerings
10.3.2.
Argentina Beyond the Pill Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Therapeutic Area
10.3.2.2.2.
By Offerings
10.3.3.
Colombia Beyond the Pill Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Therapeutic Area
10.3.3.2.2.
By Offerings
11. Middle East and
Africa Beyond the Pill Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1.
By Therapeutic Area
11.2.2.
By Offerings
11.2.3.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Beyond the Pill Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Therapeutic Area
11.3.1.2.2.
By Offerings
11.3.2.
Saudi Arabia Beyond the Pill Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Therapeutic Area
11.3.2.2.2.
By Offerings
11.3.3.
UAE Beyond the Pill Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Therapeutic Area
11.3.3.2.2.
By Offerings
11.3.4.
Kuwait Beyond the Pill Market Outlook
11.3.4.1.
Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2.
Market Share & Forecast
11.3.4.2.1.
By Therapeutic Area
11.3.4.2.2.
By Offerings
12.
Market Dynamics
12.1.
Drivers
12.2.
Challenges
13.
Market Trends & Developments
14.
Competitive Landscape
14.1.
F. Hoffmann-La Roche
AG (Flatiron Health)
14.2.
Otsuka
Pharmaceuticals Co., Ltd.
14.3.
Amgen, Inc.
14.4.
AstraZeneca Plc.
14.5.
Novartis AG
14.6.
Sanofi S.A.
14.7.
Novo Nordisk A/S
14.8.
Eli Lilly and
Company
14.9.
Johnson &
Johnson
14.10.
Teva Pharmaceutical
Industries Ltd.
15.
Strategic
Recommendations
16. About Us &
Disclaimer